BofA Gives Wave Life Sciences a Buy Rating, Eyes $38 Target
Bank of America starts coverage of Wave Life Sciences (WVE) with a Buy rating. Analyst highlights WVE-007 in obesity as a major growth driver, with peak sales above $11B.
/ 7 items
#WVE↓
Arrowhead Gene Drug Doubles Weight Loss in Obesity Trial
Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
HHS Adds Rare Diseases to Newborn Tests, Sarepta Rises
Sarepta rises as HHS recommends newborn screening for Duchenne muscular dystrophy and metachromatic leukodystrophy, aiming for earlier diagnosis and treatment.
Wave Life Sciences' Obesity Drug Shows Promising Fat Loss Without Muscle Decline
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.
FDA Feedback Rocks uniQure: Gene Therapy for Huntington’s Disease Delayed
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).
Wave Life Sciences (WVE-007): Why Experts See Big Potential for Weight Loss
Experts rate WVE-007 a Buy. It promises effective, safe weight loss, improves sugar use, and might need less frequent shots.